Will MannKind’s Luck Change the Second Time Around?

MannKind's diabetes drug, Afrezza, is back in Phase 3 trials and is showing similar promise. But can it clear the hump to approval ... unlike last time? More 

Should I Buy Zoetis? 3 Pros, 3 Cons

Animal medicines stock Zoetis has basically been treading water since its IPO. Is it a potential boomer in the making, or should you expect more flat going forward? More 

Facebook Makes the Grade and Is Now a Buy

Yes, you read that correctly. After spending months in sell territory, Facebook has made a complete turnaround in a matter of days and is now a buy More 

Trade of the Day: Novo Nordisk (NVO)

Obesity-related disease is spreading across the world -- and traders should consider the pharmaceutical companies that will grow because of that trend. More 

Attention Yield Seekers: Now Is Your Chance to Act!

In this low interest rate environment, dividends are still looking great, and these 26 stocks are about to go ex-dividend. Decide how to play them today More 

Eli Lilly to Freeze Employee Pay Increases

Eli Lilly & Co. says it is freezing employee base pay next year and cutting bonuses in a bid to lower expenses in the face of expiring drug patents. More 

50 Reasons to Take the American Consumer Seriously

Power to the people. Specifically, the American consumer. There's a reason why the June retail sales report dominated the headlines: its a critical U.S. sector More